Adagio Therapeutics, Inc. ADGI
We take great care to ensure that the data presented and summarized in this overview for Adagio Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADGI
View all-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11.8MShares$38.9 Million0.81% of portfolio
-
Deep Track Capital, LP Greenwich, CT11MShares$36.3 Million1.34% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million29.1% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.37MShares$14.5 Million0.0% of portfolio
-
Slate Path Capital LP New York, NY3.74MShares$12.4 Million0.2% of portfolio
-
Redmile Group, LLC San Francisco, CA3.07MShares$10.1 Million0.66% of portfolio
-
683 Capital Management, LLC New York, NY3MShares$9.93 Million0.9% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA1.8MShares$5.96 Million1.07% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.73MShares$5.72 Million0.13% of portfolio
Latest Institutional Activity in ADGI
Top Purchases
Top Sells
About ADGI
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Insider Transactions at ADGI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 29
2024
|
Terrance Mcguire |
SELL
Open market or private sale
|
Indirect |
112,381
-2.34%
|
$112,381
$1.66 P/Share
|
|
Jan 19
2024
|
Adimab, LLC |
SELL
Open market or private sale
|
Direct |
5,000,000
-18.74%
|
$15,000,000
$3.95 P/Share
|
|
Sep 01
2022
|
David Hering Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
8,000
+50.0%
|
$32,000
$4.52 P/Share
|
|
Aug 19
2022
|
Marc Elia |
BUY
Open market or private purchase
|
Indirect |
584,451
+5.94%
|
$2,337,804
$4.62 P/Share
|
|
Aug 18
2022
|
Marc Elia |
BUY
Open market or private purchase
|
Indirect |
1,265,549
+12.75%
|
$5,062,196
$4.31 P/Share
|
|
Aug 17
2022
|
Marc Elia |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+11.91%
|
$4,000,000
$4.04 P/Share
|
|
Mar 03
2022
|
Adimab, LLC |
SELL
Other acquisition or disposition
|
Direct |
1,158,089
-4.16%
|
-
|
|
Aug 10
2021
|
Adimab, LLC |
BUY
Conversion of derivative security
|
Direct |
25,860,700
+48.15%
|
-
|
|
Aug 10
2021
|
Tillman U. Gerngross Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
25,860,700
+48.15%
|
-
|
|
Aug 10
2021
|
Terrance Mcguire |
BUY
Open market or private purchase
|
Indirect |
500,000
+9.81%
|
$8,500,000
$17.0 P/Share
|
|
Aug 10
2021
|
Terrance Mcguire |
BUY
Conversion of derivative security
|
Indirect |
8,031,700
+50.0%
|
-
|
|
Aug 10
2021
|
Mithril Ii LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,997,000
+15.08%
|
$33,949,000
$17.0 P/Share
|
|
Aug 10
2021
|
Mithril Ii LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
9,244,580
+50.0%
|
-
|
|
Aug 10
2021
|
Ajay Royan Director |
BUY
Open market or private purchase
|
Indirect |
1,997,000
+15.08%
|
$33,949,000
$17.0 P/Share
|
|
Aug 10
2021
|
Ajay Royan Director |
BUY
Conversion of derivative security
|
Indirect |
9,244,580
+50.0%
|
-
|
|
Aug 10
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,470,000
+30.24%
|
$24,990,000
$17.0 P/Share
|
|
Aug 10
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,920,960
+50.0%
|
-
|
Last 12 Months Summary
| Open market or private sale | 5.11M shares |
|---|